Core Viewpoint - Guosen Securities reports that 3SBio (01530) is rapidly advancing its innovative drug clinical trials and has completed a significant licensing deal, maintaining steady growth in performance. The firm has raised its profit forecast, expecting the company's net profit attributable to shareholders to be 9.955 billion, 2.875 billion, and 3.212 billion yuan for 2025-2027, respectively, up from previous estimates of 2.38 billion, 2.71 billion, and 3.07 billion yuan [1][1][1] Group 1 - 3SBio's core product is progressing rapidly in global clinical development, and the company maintains an "outperform" rating [1][1][1] - Recent data from the STIC conference shows that the clinical phase II study of 707 in combination with chemotherapy for 1L NSCLC demonstrates good efficacy and safety in both sqNSCLC and nsqNSCLC, supporting the continuation of clinical phase III studies [1][1][1] Group 2 - Pfizer has announced a global clinical strategy for 707, with the first wave of recent clinical trials focusing on two key phase III studies (NSCLC 1L; mCRC 1L) and plans to initiate five additional studies soon [1][1][1] - The second wave of development plans by Pfizer is expected to add 10 new indications and over 10 novel combination regimens by the end of 2026, aiming to replace existing standard treatments such as PD-(L)1 inhibitors and VEGF inhibitors with 707 as a new cornerstone therapy [1][1][1]